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Abstract
Background: Preterm birth complications are the leading cause of deaths for children under five years. Antenatal
corticosteroids (ACS) are effective at reducing mortality and serious morbidity amongst infants born at <34 weeks
gestation. WHO guidelines strongly recommend use of ACS for women at risk of imminent preterm birth where
gestational age, imminent preterm birth, and risk of maternal infection can be assessed, and appropriate maternal/
newborn care provided. However, coverage remains low in high-burden countries for reasons not previously
systematically investigated.
Methods: The bottleneck analysis tool was applied in 12 countries in Africa and Asia as part of the Every Newborn
Action Plan process. Country workshops involved technical experts to complete the survey tool, which is designed
to synthesise and grade health system “bottlenecks”, factors that hinder the scale up, of maternal-newborn
intervention packages. We used quantitative and qualitative methods to analyse the bottleneck data, combined
with literature review, to present priority bottlenecks and actions relevant to different health system building blocks
for ACS.
Results: Eleven out of twelve countries provided data in response to the ACS questionnaire. Health system
building blocks most frequently reported as having significant or very major bottlenecks were health information
systems (11 countries), essential medical products and technologies (9 out of 11 countries) and health service
delivery (9 out of 11 countries). Bottlenecks included absence of coverage data, poor gestational age metrics, lack
of national essential medicines listing, discrepancies between prescribing authority and provider cadres managing
care, delays due to referral, and lack of supervision, mentoring and quality improvement systems.
Conclusions: Analysis centred on health system building blocks in which 9 or more countries (>75%) reported
very major or significant bottlenecks. Health information systems should include improved gestational age
assessment and track ACS coverage, use and outcomes. Better health service delivery requires clarified policy
assigning roles by level of care and cadre of provider, dependent on capability to assess gestational age and risk of
preterm birth, and the implementation of guidelines with adequate supervision, mentoring and quality
improvement systems, including audit and feedback. National essential medicines lists should include
dexamethasone for antenatal use, and dexamethasone should be integrated into supply logistics.
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Background
Each year, an estimated 15 million infants are born pre-
mature, representing over one in ten live births [1].
Complications from prematurity are the leading global
cause of deaths in children under five [2], with over one
million annual deaths [3], particularly from pulmonary
immaturity and resultant respiratory distress syndrome
(RDS) [4,5]. A preventive approach, first demonstrated
to be effective in 1972, is the administration of antenatal
corticosteroids (ACS) to mothers at risk of imminent
preterm birth in order to stimulate fetal lung maturation
[6]. Subsequent trials have established the safety and
efficacy of ACS for women at risk of imminent preterm
birth, with a meta-analysis of 21 studies finding a
roughly one-third reduction in risk of neonatal death
[4]. A subgroup analysis of the four trials conducted in
middle-income countries (MICs) found a further reduc-
tion of around 50% in mortality, suggesting possible
greater benefit in lower-resource settings [7].
Reducing the burden of preterm birth requires effec-
tive maternal care including comprehensive obstetric
care (with caesarean section, if needed [8]), and specific
care for the preterm newborn [9-11]. ACS administra-
tion is a critical component of this care. A recent large,
six-country study (Antenatal Corticosteroids Trial, or
ACT) extending ACS to community and primary care
settings with lower level workers, found adverse out-
comes in neonatal mortality, stillbirth and maternal
infection, underlining the importance of trained health
professionals able to accurately assess gestational age
and provide ACS in hospital settings with adequate sup-
portive care [12]. Currently, organisations including the
new WHO guidelines on interventions to improve pre-
term birth outcomes [13] recommend a single course of
ACS (dexamethasone or betamethasone, 24 mg adminis-
tered by intramuscular injection in divided doses) to
mothers less than 34 completed weeks of gestation, with
risk of imminent preterm birth (anticipated within the
subsequent 7 days) [15-20]. Safe and effective use of
ACS depends on the accuracy of gestational age assess-
ment, correct diagnosis of imminent preterm birth, and
adequate maternal and newborn care (Figure 1). ACS is
contraindicated for women with chorioamnionitis.
There has been rapid adoption of ACS use in high-
income countries (HICs) since the mid-1990s [20], with
coverage rates of over 90%. Yet coverage appears to remain
low in low- and middle-income countries (LMICs), where
99% of all neonatal deaths occur [21]. Available estimates
suggest that coverage varies greatly in LMIC facilities but is
generally low even at the highest levels of care (Table 1).
Increased safe and effective use of ACS has the potential to
save an estimated 214,300 newborns each year with use for
those births already occurring in hospitals with the appro-
priate package of linked care [22].
ACS is only one part of obstetric and preterm birth
management [8] and should be part of initiatives to
increase institutional birth rates and improve antenatal
and intrapartum care coverage, quality and equity. Effec-
tiveness and safety also critically require adequate neonatal
care including thermal care, breastfeeding, resuscitation
[11], kangaroo mother care [10], and availability of inpati-
ent care of small and sick newborns [9].
Low coverage of ACS has been variously attributed to
lack of guidelines, prescribing authority, provider aware-
ness or skills, drug availability, and patient access to
appropriate facilities [23]. However, the health system
barriers to increased uptake of ACS have not previously
been systematically examined.
This paper presents the results of a systematic multi-
country analysis of barriers to uptake of ACS for preterm
birth. In this analysis, we aim to identify priority health
system building blocks facing common and critical bot-
tlenecks to scaling up this life-saving intervention. We
additionally discuss policy and programmatic implica-
tions and recommend priority actions drawn from the
survey responses, existing evidence, and programme
experience.
Objectives of this paper are as follows:
1. Use a 12-country analysis to explore health system
bottlenecks affecting the scale-up of ACS.
2. Present the solutions to overcome the most signifi-
cant bottlenecks including insights from respondent
countries, literature review and programme experience.
3. Discuss policy and programmatic implications and
propose priority actions.
Methods
This study used quantitative and qualitative research
methods to collect information, assess health system bot-
tlenecks and identify solutions to scale-up of maternal and
newborn care interventions in 12 countries: Afghanistan,
Cameroon, Democratic Republic of Congo (DRC), Kenya,
Malawi, Nigeria, Uganda, Bangladesh, India, Nepal,
Pakistan and Vietnam. The methodology has been
discussed in detail previously and in paper 1 of this sup-
plement [24,25].
Data collection
The maternal-newborn bottleneck analysis tool was
developed as part of the Every Newborn Action Plan
(ENAP) process to assist countries in identifying con-
text-specific bottlenecks to the scale-up and provision of
maternal and newborn health interventions across seven
health system building blocks [25]. The tool was utilised
during a series of national consultations supported by
the global Every Newborn Steering Group between July
1st and December 31st 2013 (see Additional file 1). The
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workshops for each country included participants from
national ministries of health, United Nations (UN) agen-
cies, the private sector, non-governmental organisations,
professional bodies, academia, bilateral agencies, and
other stakeholders. For each workshop, a facilitator,
orientated on the tool, coordinated the process and
Figure 1 Levels of care for the safe administration of antenatal corticosteroids for the management of preterm labour. Facility with
comprehensive emergency obstetric and newborn care image source: Mai Simonsen/Save the Children. Facility with basic emergency obstetric
and newborn care image source: Chris Taylor/Save the Children. In the community image source: Parth Sanyal/Save the Children
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facilitated groups to reach consensus on the specific
bottlenecks for each health system building block. This
paper, third in the series, is focused on antenatal corti-
costeroids for the management of preterm birth.
Data analysis methods
We graded bottlenecks for each health system building
block using one of the following options: not a bottle-
neck (=1), minor bottleneck (=2), significant bottleneck
(=3), or very major bottleneck (=4). We first present the
grading in heat maps according to the very major or sig-
nificant health system bottlenecks as reported by all 12
countries, then by mortality contexts (neonatal mortality
rate (NMR) <30 or NMR ≥30 deaths per 1000 live
births) and by region (countries in Africa and countries
in Asia). We developed a second heat map showing the
specific grading of bottlenecks for each health system
building block by individual country. Survey responses
were analysed for common specific bottlenecks, defined
to be those reported by at least 3 countries. Where the
same specific bottleneck was reported under more than
one building block, it was categorised in accordance
with the relevant survey question, or under the building
block where most countries reported the specific
bottleneck.
Finally, we categorised context-specific solutions for
scaling up under the subcategories of corresponding
bottlenecks within each health system building block.
Results
Eleven out of twelve country teams submitted their
responses to the ACS questionnaire. Cameroon, Demo-
cratic Republic of the Congo (DRC), Kenya, Malawi,
Nigeria, Uganda, Bangladesh, Nepal, and Vietnam
returned national-level responses. Pakistan provided sub-
national data from all provinces, Gilgit-Baltistan, and Azad
Jammu and Kashmir, excluding two tribal territories.
Sindh province, Pakistan, did not provide a grade for com-
munity ownership and partnership. India returned data
from three states: Andhra Pradesh, Odisha, and Rajasthan.
Rajasthan state completed the questionnaire and listed
specific bottlenecks, but did not provide ratings for any
building block. India responded to the earlier version of
the questionnaire with fewer questions. Afghanistan, the
twelfth country, returned national-level survey data with-
out responses to the ACS portion and therefore is not
included in our analysis.
An overview of grading for the health system building
blocks, for all countries and by mortality setting and geo-
graphy, is shown in Figure 2. More building blocks were
graded as having significant or very major bottlenecks in
countries with higher NMR; all four countries with NMR
≥30 (DRC, Nigeria, India, and Pakistan) reported very
major or significant bottlenecks across all seven health sys-
tem building blocks. Health system building blocks were
graded poorly by a comparable proportion of countries in
Africa and Asia, except for leadership and governance,
Table 1. Existing estimates of antenatal corticosteroid coverage using World Bank income groupings
Country Coverage
estimate (%)
Indicator Year
42 countries with 90% of child deaths 5 All preterm births 2000
[38]
In facility
WHO Multi-country Survey
7 low income countries
19 middle income countries
27
58
Eligible women 26-34 weeks at facilities with >1,000 deliveries per year and
capacity for caesarean section
2014
[39]
75 Countdown countries
34 low income countries + 40 middle
income countries
41 Preterm births in secondary and tertiary facilities 2014
[40]
Cameroon (middle income country) 10 Facility-based RH providers using ACS 2005
[41]
Brazil (middle income country) 4 Eligible women 28-33+6 weeks in public maternal hospitals in Rio de Janeiro 1999
[42]
Ecuador (middle income country) 35 Eligible women 24-34+6 weeks in influential reference hospitals in capital
cities
2010
[43]
El Salvador (middle income country) 55
Uruguay (high income country) 71
Indonesia (middle income country) 8 Eligible women <34 weeks in tertiary and district hospitals 2008
[44]
Malaysia (middle income country) 28
Philippines (middle income country) 7
Thailand (middle income country) 74
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more commonly reported as a very major or significant
bottleneck by African respondents.
Building block grading for each respondent country is
summarised in Figure 3. Very major or significant bot-
tlenecks were reported by at least 75% of country teams
(at least 9 of 11) in three building blocks: health infor-
mation systems (all countries), essential medical pro-
ducts and technologies (9 of 11 countries) and health
service delivery (9 of 11 countries).
Table 2 summarises priority actions proposed by
country teams to address specific bottlenecks to ACS
scale-up. These solutions are grouped by health system
building block. Common bottlenecks (reported by at
least 3 countries) to scale-up of ACS are summarised in
additional file 2 (table S1), along with underlying causes
where reported.
Leadership and governance bottlenecks and solutions
Leadership and governance was graded as a very major
or significant bottleneck by 7 of 11 country teams
(Figure 2), representing a larger proportion of Asian
countries (4 of 5 countries in Asia, compared to 3 of
6 countries in Africa). The most commonly cited speci-
fic bottleneck was inadequate guidelines on ACS use,
cited by 9 of 11 country teams. Of these, 5 country
teams (4 in Asia) reported no clear guidelines on ACS
for management of preterm birth, and 4 country teams
(all in Africa) reported available guidelines, which were
either outdated or not disseminated.
Proposed solutions included development (or update)
and dissemination of national guidelines and protocols
on prevention and management of preterm labour,
including ACS. Updated WHO guidelines will be useful
to inform national guidelines.
Health financing bottlenecks and solutions
Health financing was graded as a very major or signifi-
cant bottleneck by 8 of 11 country teams. The most
commonly cited specific bottleneck was insufficient
funding, reported by 9 country teams, with 8 indicating
a lack of priority or policy as the underlying cause.
Proposed solutions included increased advocacy and
leadership, particularly with funding and budget alloca-
tion, for preterm birth prevention, management and
care including ACS.
Health workforce bottlenecks and solutions
Health workforce was graded as a very major or significant
bottleneck by 7 of 11 country teams. All country teams
questioned reported a shortage of health workers espe-
cially in higher cadres, inadequate training, and inadequate
supervision or mentoring. India did not provide an answer
to the question on health worker shortages.
Proposed solutions included integration of ACS into
pre-service and in-service training, development and dis-
semination of job aids, and consideration of expanded
prescription authority for more cadres of health workers.
Essential medical products and technologies bottlenecks
and solutions
Essential medical products and technologies was graded
as a very major or significant bottleneck by 9 of
11 country teams. All 11 country teams cited as a specific
Figure 2 Very major or significant health system bottlenecks for antenatal corticosteroids for management of preterm birth. NMR:
Neonatal Mortality Rate. *Cameroon, Kenya, Malawi, Uganda, Bangladesh, Nepal, Vietnam. **Democratic Republic of Congo, Nigeria, Afghanistan,
India, Pakistan. See additional file 2 for more details.
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bottleneck the lack of inclusion of ACS on the national
essential medicines list (NEML) for fetal lung matura-
tion, though all included dexamethasone for other indi-
cations. Of 8 country teams reporting inadequate
procurement or distribution of ACS, 6 cited the lack of
policy or NEML listing for fetal lung (or other lack of
alignment between supply chain policy and ACS recom-
mendations) as a direct cause of lack of integration into
supply chain system. Additionally, no respondent coun-
try included ACS in quantification and forecasting, and
none reported having an indicator for ACS drug
availability.
Figure 3 Individual country grading of health system bottlenecks for antenatal corticosteroids for the management of preterm birth.
Part A: Heat map showing individual country grading of health system bottlenecks for antenatal corticosteroids for the management of preterm
birth. Part B: Table showing total number of countries grading significant or major for calculating priority building blocks. DRC: Democratic
Republic of the Congo. See Additional file 2 for more details.
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Proposed solutions included listing of ACS drugs on
NEMLs for a fetal lung maturation indication, develop-
ment and dissemination of guidelines, and software to
support needs-based forecasting and procurement.
Health service delivery bottlenecks and solutions
Health service delivery was graded as a very major or sig-
nificant bottleneck by 9 of 11 country teams. All country
teams reported having inadequate or non-existent quality
Table 2. Country-recommended priority actions for addressing common bottlenecks to scaling up antenatal
corticosteroids
Health system building
block
Sub-category Priority actions
Leadership and
governance
Policy and guidelines • Develop, update and disseminate the national policy on prevention and management
of preterm labour; this should include policy on ACS use
• Advocate for newborn health to be made as a priority
• Develop national clinical protocols and guidelines on management of preterm labour
Health financing Funding/budget allocation • Increase funding / budget allocation for newborn care
• Advocate and lobby for more funding from partners in newborn health
Cost of antenatal
corticosteroids
• Assess financial implications and develop financial policy for supplies and services to
deliver this intervention to beneficiaries
• Include antenatal corticosteroids as part of the free MNCH policy
• Scale up obstetric kits by including relevant newborn drugs such as antenatal
corticosteroids
Health workforce Policy restriction for
prescription and
administration
• Authorise all skilled births attendants to prescribe and administer ACS
Job descriptions/job aids • Develop and disseminate job aids
Shortage of qualified staff • Recruit and train competent health providers
• Develop an electronic database to track training activities and identify needs
• Ensure staffing norms are in line with WHO recommendations
Competency and training • Strengthen competency based pre-service and in-service training, and on job training
to capture use of ACS by health providers for fetal lung maturation
• Include ACS training in skilled birth attendant evaluation
Health service delivery Service availability • Develop and disseminate national guidelines in health facilities
• Establish follow-up visits to monitor availability and use of ACS in all health facilities
Quality of care • Establish a supportive supervision and mentoring mechanism with a reward system;
• Regular integrated monitoring visits to ensure compliance to protocols;
• Integrate ACS use in clinical audits and reviews;
Referral systems • Involve all stakeholders to improve infrastructure for timely referral (road network)
• Build district-level capacity to monitor appropriate use of ambulances and ensure
adequate maintenance
Essential medical products
and technologies
Procurement policy • Include ACS in national essential medicines list with appropriate indication (fetal lung
maturation)
Drug availability • Develop and disseminate policy in health facilities to enhance procurement
Logistics management
information systems (LMIS)
• Estimate needs based on number/estimate of preterm birth load at health facilities
• Build staff capacity for logistics management
Health information system Data collection and reporting • Define indicator(s) for tracking ACS use and incorporate into national system
• Strengthen monitoring mechanisms such as regular monitoring and evaluation visits,
documentation through use of program data.
• Conduct regular review meetings on data management at all levels
Community ownership
and participation
Knowledge / awareness • Conduct integrated community maternal and newborn education and campaigns in
local languages
• Improve community awareness on newborn health by adding newborn information to
maternal awareness documents, campaigns, media, etc.
Community participation /
engagement
• Strengthen community leaders and male involvement through innovative approaches;
• Strengthen functioning of existing community units with nationwide community
awareness initiatives on newborn health
• Health facilities to come up with innovative ways of involving men e.g. set aside time
for couples during antenatal visits and time for adolescents
Demand for preterm birth care • Scale up tribal empowerment project to address socio-cultural barriers to newborn
care
• Utilise community radio and mobile applications
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monitoring and improvement systems, and 9 country
teams noted a lack of alignment between ACS prescrib-
ing authority and health worker cadres providing care for
women at risk of preterm birth. Additionally, 7 countries
cited delays due to referrals as a specific bottleneck.
Table S3 and S4 of the Additional file 2 summarises
levels of care where ACS is allowed and health worker
cadres permitted to prescribe and/or administer ACS, as
reported by country teams.
Proposed solutions included development and dissemi-
nation of guidelines across facilities, creation of supervision
and mentoring systems, integration into clinical audits and
reviews, and strengthened referral systems.
Health information system bottlenecks and solutions
Health information system was identified as the most
problematic building block, with all 11 country teams
reporting very major or significant bottlenecks.
Responses to health information systems questions
revealed an almost complete absence of defined and
standardised indicators for ACS use, with the exception
of Nepal and one province in Pakistan, where country
teams reported that ACS use was tracked on parto-
graphs. No countries reported having an indicator for
ACS drug availability. Moreover, no countries included
ACS use in clinical audits or perinatal reviews.
Proposed solutions included creation of indicator(s)
for ACS use and integration of ACS data into record-
keeping systems and regular reviews.
Community ownership and partnership bottlenecks and
solutions
Community engagement was graded as a very major or
significant bottleneck by 8 of 11 country teams. The most
commonly cited specific bottlenecks were lack of aware-
ness and initiatives targeted at raising awareness of pre-
term birth risks and management (9 countries), and the
absence of an accessible facility or transportation to reach
a facility where ACS could be administered (9 countries).
Proposed solutions included leveraging existing com-
munity outreach infrastructure, such as community
groups, opinion leaders, and media.
Discussion
This systematic analysis of ACS use in 11 high-burden
countries, which together account for over half of
maternal and newborn deaths, has identified commonly
experienced health system bottlenecks to scaling up
ACS for management of preterm birth. A comprehen-
sive approach to preterm birth should include strategies
for prevention as well as management; however, the
menu for high-impact, evidence-based preterm birth
prevention is currently limited [26]. In high-income set-
tings, reductions in the burden of preterm birth can
largely be traced to improved care of preterm infants,
which has yet to achieve major traction or wide-scale
use even for simpler care such as feeding support, kan-
garoo mother care and infection prevention and treat-
ment [27]. There is also considerable scope for impact
through management of preterm birth, including ACS
which is highly effective when provided by adequately
trained health professionals in hospital settings where
adequate maternal and neonatal follow-up and support
are possible.
The important principle of “do no harm” and potential
risks of ACS have been highlighted recently through the
ACT trial. The benefits of ACS are dependent on high
coverage in preterm babies <34 weeks; benefit is not
expected or is marginal after 34 weeks, and risks increase
close to term. Targeting based on gestational age and
more accurate diagnosis of imminent preterm birth are
therefore key aspects of effective, safe use as underscored
in WHO guidelines. In addition, ACS alone cannot be a
magic bullet; the preterm infant still requires a minimum
of supportive care including warmth and feeding support,
and if <32 weeks gestation is more likely to require oxygen
therapy and respiratory support. Approximately half of the
births in the ACT trial occurred at home or low-level pri-
mary care facilities [12].
Despite variation across the 11 countries that
responded to the survey, the greatest barriers were con-
sistent, highlighting three priority health system building
blocks–health information systems, health service deliv-
ery and essential medical products and technologies–
with the most critical common bottlenecks. Drawing
from country programme experience, and evidence from
literature (Table 2), this paper outlines potential solu-
tions for programme managers and policymakers facing
similar barriers.
Health information systems priority actions
Data on ACS coverage, use, and outcomes including
safety were absent in nearly all countries. To enable
continuous and quantitative assessment of ACS pro-
grammes, appropriate indicators need to be defined, and
these data integrated into existing health information
systems in order to allow tracking and comparison at
facility, district, and national levels. ACS coverage data
are one of the priority indicators identified in the Every
Newborn Action Plan [28]. Coverage data are lacking
and should also aim to assess false positives (women
treated whose babies are born after 34 completed
weeks).
Use of data for quality improvement would be aided if
ACS were systematically included in safe childbirth
checklists, partographs, clinical audits, and perinatal
death reviews [29]. Data are also needed on process
such as logistics and stock out. Two case studies of in-
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country implementation programmes provide examples
of data collection and recordkeeping systems for ACS
use, and how audit and feedback mechanisms using
these records can be harnessed to improve quality of
care for the management of preterm birth (Figure 4).
Health service delivery priority actions
Estimates suggest ACS coverage in LMICs is generally
low even in tertiary facilities (Table 1), consistent with
the poor grading of health service delivery among
respondent country teams. All 11 countries in this ana-
lysis are among the 75 Countdown to 2015 countries
with an estimate of 41% (weighted average) coverage of
preterm births in secondary and tertiary facilities. Eight
of 11 countries were also included in the WHO Multi-
country Survey estimate of coverage in high-volume
facilities; these were DRC (16%), Kenya (32%), Nigeria
(30%), Uganda (27%), India (69%), Nepal (20%), Pakistan
(63%), and Vietnam (52%). These estimates are likely to
be higher than the national average as the survey meth-
odology sampled only large facilities from the capital
city and two randomly selected provinces. National
population coverage with ACS is likely to be much
lower than facility coverage estimates, as a large propor-
tion of births take place outside of high-volume facilities
or outside any facility. In the 11 countries, institutional
delivery rates (in any facility) ranged from 33% in Ban-
gladesh to 92% in Vietnam, according to data compiled
by UNICEF in 2015 [30].
Available evidence supports focusing scale-up efforts
in facilities with the capacity for gestational age assess-
ment and diagnosis of women at risk of imminent
Figure 4 The use of continuous quality improvement for antenatal corticosteroid use in Malawi and Uganda. ACS: antenatal
corticosteroids. PDSA: Plan-Do-Study-Act
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preterm birth, as well as ongoing support for preterm
infants and well-functioning maternity wards [4]. The
recent study (ACT) which extended ACS to include
non-hospital facilities in six countries (including Kenya,
India, and Pakistan) found increased perinatal mortality
as well as increased rates of presumed maternal infec-
tion [12]. The specific cause(s) of newborn mortality
were not ascertainable, but service delivery challenges
included limited ability to estimate gestational age and
accurately diagnose high risk of preterm birth. As a con-
sequence, ACS was under prescribed for preterm and
early preterm babies likely to benefit from treatment
and overprescribed to babies born at or near term,
when ACS may have increased risks.
With clear evidence for use in hospitals in HICs with
adequate neonatal support and reason for caution at
lower-level facilities in LIC settings, programmatic scale-
up is best focused on higher-level and high-volume
facilities, where resources can also be used to produce
significant impact cost-effectively and also improve
targeting and safety tracking. Increased population cov-
erage will then depend on increased and timely identifi-
cation and referral of at-risk women, both in lower-level
facilities and in homes. Systemic improvements are
needed to encourage institutional deliveries with skilled
birth attendants and to strengthen referral systems,
while guidelines and training at lower levels of care will
be critical to building capacity for timely identification.
Expanded care such as a pre-referral dose may also
improve care by allowing a longer time for ACS to take
effect. However, such steps must be considered cau-
tiously by each country based on the capacity of lower-
level facilities to provide adequate care to ensure safety.
Human resource and skills for service delivery
Within hospitals, coverage is often limited by inadequate
numbers of physicians or other providers present and
also adequately trained to assess gestational age, diagnose
high risk of preterm birth, and authorised to prescribe
and administer ACS. The majority of countries reported
both a shortage of health workers at higher cadres and a
mismatch between provider cadres allowed to prescribe
ACS and those cadres likely to be caring for women at
risk of preterm birth (Table S2, additional file 2).
Expanded prescribing authority for midwives provid-
ing care to pregnant women could greatly increase the
capacity of hospitals to manage preterm birth with ACS.
However, any change in policy must be considered
based on the capability to correctly diagnose conditions,
which lead to preterm birth and provide adequate sup-
portive care to both mother and baby. Currently WHO
only recommends administration of ACS by doctors and
advanced level associate clinicians and recommends
against use by nurses and auxiliary nurses. Prescription
and administration of ACS by non-advanced associate
clinicians has not been evaluated by the WHO due to
lack of rigorous evaluation of this question [31].
The WHO recommends cautious consideration of
ACS administration by midwives and auxiliary nurse-
midwives (ANMs) in LMICs with shortages of physi-
cians-those settings described by respondent countries.
Consideration of expanded prescribing authority should
be made in the context of rigorous research [31]. In the
absence of prescribing authority, health workers provid-
ing care to mothers still have an important role in iden-
tifying potential risk of preterm birth and ensuring rapid
and safe referral.
All countries reported a lack of training in assessing
gestational age, recognition of high risk of preterm birth
and in management of preterm birth using ACS as
well as inadequate supervision and mentoring systems.
In-service training and increased support, both for
cadres authorised to prescribe and administer ACS and
for cadres involved in identification of risk and referral,
are also critical to any scale-up effort.
Guidelines implementation and quality improvement
For any policy to reach every mother and every newborn,
clear guidelines and adequate training must reach all
relevant cadres of health worker and levels of care. As
indicated by the country teams’ responses to leadership
and governance questions, it is critical both to develop
clear guidelines and to ensure active dissemination. An
active model of dissemination should ideally integrate
systems of supervision, mentoring, and monitoring of
quality improvement - all areas reported as inadequate
by all 11 country teams.
A study of active dissemination in the United States
showed that use of local opinion leaders, technical
updates, reminders, interactive small-group learning,
and audit and feedback were effective in accelerating
facility uptake of ACS. These five elements were also
effective in increasing use of a maternal health interven-
tion in LMICs, with a structure reflecting the differing
needs of low-resource settings. Figure 5 shows the five-
component structure of the interventions in these two
RCTs and details their implementation in each setting.
Figure 6 outlines a program with similar features cur-
rently being studied in a facility in Cambodia. In parti-
cular, the audit and feedback component provides one
model for continuous quality monitoring and improve-
ment, an essential part of quality implementation of
guidelines. This pilot model also provides a further
example of the role of the continuous use of outcome
data in improving safety and quality of care.
Essential medical products and technologies priority
actions
Corticosteroids for ACS treatment are inexpensive (often
under 1 USD for a full course) and are often assumed to
Liu et al. BMC Pregnancy and Childbirth 2015, 15(Suppl 2):S3
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be widely available. Yet most respondents indicated
shortages at the country level, primarily attributed to a
lack of supporting policy or effective logistics systems.
NEML listing for the fetal lung maturation indication is
essential to prioritisation for procurement as well as inte-
gration into supply chain, from forecasting to distribution.
Adequate procurement further depends on development
and dissemination of guidelines on ACS use, including
clarity on the choice of corticosteroid and appropriate
regimen. Two corticosteroids, dexamethasone and beta-
methasone, have been shown to be safe and effective to
manage preterm birth. Betamethasone is sometimes
preferred in HICs due to limited evidence suggesting
better outcomes (44% reduction in RDS and 33% reduc-
tion in neonatal mortality versus placebo or no treat-
ment, compared with 20% reduction in RDS and 28%
Figure 5 An adaptable model for active dissemination of guidelines on the use of antenatal corticosteroids. ACS: antenatal
corticosteroids. LMICs: low and middle income countries
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reduction in neonatal mortality for dexamethasone ver-
sus placebo or no treatment) and potentially lower risk
of maternal infection [4].
However, evidence on dexamethasone still conclusively
supports its overall safe and effective use for management
of preterm birth. A meta-analysis of 9 studies directly
comparing dexamethasone with betamethasone further
found no statistically significant differences apart from a
greater reduction in intraventricular haemorrhage using
dexamethasone (RR 0.44, 95% CI 0.21 to 0.92, 4 studies,
549 infants). A large RCT directly comparing dexametha-
sone to betamethasone is currently underway [32].
Critically, only dexamethasone is a feasible choice for
scale-up in most LMICs. While dexamethasone is widely
available from international suppliers for a variety of indi-
cations, the formulation of betamethasone supported by
most evidence (a suspension of betamethasone acetate in
betamethasone phosphate, rather than betamethasone
phosphate alone) has been subject to global shortages
[33] and costs 25 times as much as dexamethasone per
course of ACS [34].
Dexamethasone also faces fewer policy hurdles to
increased use for management of preterm birth. With a
variety of uses, dexamethasone in the recommended for-
mulation is already registered, listed on the NEML, and
included in procurement and supply chain in all 11
countries, for other indications. Dexamethasone is the
only ACS listed on the WHO EML with a fetal lung
maturation indication [35].
National policies, in line with the current WHO
guideline, should therefore focus on promoting appro-
priate use of dexamethasone through procurement pol-
icy, clear guidelines, and integration into forecasting,
procurement, and supply chain.
Figure 6 Active dissemination of guidelines on the use of antenatal corticosteroids in Phnom Penh, Cambodia. ACS: antenatal
corticosteroids. LMIC: Low and middle income countries
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Limitations and implications for further research
Soliciting responses from a wide range of in-country
partners and practitioners in maternal and newborn
health captured context-specific challenges and gener-
ated collaborative solution ideas. The grading process
also created consensus around priority bottlenecks and
health system building blocks to be addressed. However,
these consensus views are subjective. The quality and
amount of information also varied depending on the
level of knowledge of participants on health system
issues and on workshop facilitation. In addition, bottle-
necks were reported as perceived bottlenecks relative to
the other health system building blocks. National-level
assessment may mask regional disparities, particularly
between urban and rural areas. This comprehensive
questionnaire may have led to respondent fatigue, but
Figure 7 Key messages and action points for scale-up of antenatal corticosteroids for management of preterm birth. ACS: antenatal
corticosteroids
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this effect is least significant for ACS as the first inter-
vention in the bottleneck analysis tool. For India and
Pakistan, subnational responses may not mirror all
national-level challenges. However, Pakistan submitted
responses from all regions except two tribal territories,
and although India returned data from only three of its
28 states, these areas are amongst the poorest states and
include populations similar to those of Vietnam, Kenya,
and DRC [36].
Further research is needed to establish the effective-
ness of the solutions described here, especially in the
context of ACS use in LMIC hospital settings where
most of the world’s births now occur. To date the evi-
dence on ACS is primarily from HIC settings with neo-
natal intensive care [4] or the ACT trial from low-level
settings with less-skilled workers [12]. The evidence
base could be greatly advanced in LMIC settings, for
instance through a multi-country, cluster-randomised
trial in LMIC hospitals to assess the mortality impact
and safety of a package optimising gestational age
(where first trimester ultrasound is not routine) and
clinical assessment of mothers, including risk of preterm
birth and possible maternal infection, whilst providing
appropriate maternal and newborn care. Given the lack
of pharmacokinetic and dynamics data for both dexa-
methasone and betamethasone, other research questions
include optimal dosage regimens. Data are now even
more critically important and this gap is urgent to
address, possibly for coverage and outcome data that
could be tracked in routine health management infor-
mation systems [29]. Further work is also needed to
define signal functions for newborns by level of care. A
signal function on ACS could be incorporated into
existing monitoring systems, such as the signal functions
for basic and comprehensive emergency obstetric care,
to ensure consistent tracking of maternal and newborn
interventions along the continuum of care [37].
Another important track of research is to improve the
accuracy and also feasibility of gestational age assess-
ment, including testing tools to improve accuracy of last
menstrual period assessment, use of ultrasound dating
in later pregnancy and ways to promote better recording
in notes and use of the data by clinicians. Key messages
and actions are summarised in Figure 7.
Conclusions
ACS for management of preterm birth has been a stan-
dard of care in wealthy countries for over 20 years, yet
is greatly underused in low-resource countries, where
complications of preterm birth have recently become
the leading cause of death in children under 5. Preterm
infants are over 12 times more likely to die in the poor-
est compared to the richest countries, and infants in the
poorest countries have a survival rate at 32 weeks
similar to that of infants born in the richest countries at
25 weeks. This systematic bottleneck analysis using data
from 11 countries identifies critical areas of focus and
suggests a set of actionable solutions for extending this
inexpensive, high-impact intervention, whilst also pro-
moting the tracking for safety, potentially saving hun-
dreds of thousands of lives each year.
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